Experimental Hemophilia A Drug Loses Effectiveness Over Time, Efficacy Questionable After 8th Year

According to a publication from Reuters, based on early clinical data, American biotechnology company BioMarin Pharmaceuticals believes that a single injection of its experimental hemophilia A drug could relieve symptoms…

Continue Reading Experimental Hemophilia A Drug Loses Effectiveness Over Time, Efficacy Questionable After 8th Year

Loma Linda University Cures Their First Sickle Cell Disease Patient with Stem Cell Transplant

LLUCH Loma Linda University Children's Hospital (LLUCH) is one of six hospitals in the University's health system. They are a faith-based system located in Southern California. They are the only…

Continue Reading Loma Linda University Cures Their First Sickle Cell Disease Patient with Stem Cell Transplant

uniQure Receives FDA Fast Track Designation for AMT 130 Gene Therapy for the Treatment of Huntingtons Disease

LEXINGTON, Mass. and AMSTERDAM, the Netherlands - uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,  announced that the U.S. Food and Drug…

Continue Reading uniQure Receives FDA Fast Track Designation for AMT 130 Gene Therapy for the Treatment of Huntingtons Disease

The Struggles of being a Rare Disease Patient in China

The State of Rare Diseases in China The Illness Challenge Foundation (ICF) is an organization devoted to easing the burdens that rare disease patients living in China face. They accomplish this…

Continue Reading The Struggles of being a Rare Disease Patient in China
Preventive Use of Extended Half-Life Therapies Provides Enhanced Benefit for Hemophilia A Patients
source: pixabay.com

Preventive Use of Extended Half-Life Therapies Provides Enhanced Benefit for Hemophilia A Patients

According to a story from BioSpace, a recent study revealed that hemophilia A patients were less likely to experience bleeds when they used new, extended half-life therapies on a preventive…

Continue Reading Preventive Use of Extended Half-Life Therapies Provides Enhanced Benefit for Hemophilia A Patients

Secondary Long-Term Prophylaxis Shows Promise for Patients with Severe von Willebrand Disease (vWD)

A recent article in the National Hemophilia Foundation news quotes the Blood Transfusion journal's report on the results of a study conducted under the lead of Dr. Flora Peyvandi, Medical…

Continue Reading Secondary Long-Term Prophylaxis Shows Promise for Patients with Severe von Willebrand Disease (vWD)

Updates From Spark Highlight the Potential of Gene Therapy for Treating Hemophilia

According to a story from Hemophilia News Today, the drug developer Spark Therapeutics, Inc., has recently released several updates in regards to a number of its experimental gene therapies that…

Continue Reading Updates From Spark Highlight the Potential of Gene Therapy for Treating Hemophilia
Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects
Source: Pixabay

Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects

Passsage Bio Passage Bio has just announced that they've received 115.5 million dollars to help advance their development of gene therapies. They will begin by using the funds to further…

Continue Reading Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects

Press Release: uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B

Full Patient Enrollment in Study Expected by Year-End 2019 LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for…

Continue Reading Press Release: uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B
The Latest in St. Jude Research on Blood Cancers and Blood Disorders
qimono / Pixabay

The Latest in St. Jude Research on Blood Cancers and Blood Disorders

According to a story from EurekAlert!, the 60th Annual Meeting of the American Society of Hematology featured a number of different presentations of the latest research from St. Jude Children's…

Continue Reading The Latest in St. Jude Research on Blood Cancers and Blood Disorders